HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

6- (4- (3- (2- methylpyrrolidin- 1- yl)propoxy)phenyl)- 2H- pyridazin- 3- one

a histamine H3 receptor inverse agonist; structure in first source

Also Known As:

CEP 26401; CEP-26401; CEP26401; irdabisant

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - 6-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-pyridazin-3-one: 3
  - Pyridazines: 11
    - 6-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-pyridazin-3-one: 3

Experts

1.	Aimone, Lisa D: 2 articles (01/2012 - 07/2011)
2.	Ator, Mark A: 2 articles (01/2012 - 07/2011)
3.	Bacon, Edward R: 2 articles (01/2012 - 07/2011)
4.	Hudkins, Robert L: 2 articles (01/2012 - 07/2011)
5.	Mallamo, John P: 2 articles (01/2012 - 07/2011)
6.	Marino, Michael J: 2 articles (01/2012 - 07/2011)
7.	Mathiasen, Joanne R: 2 articles (01/2012 - 07/2011)
8.	Raddatz, Rita: 2 articles (01/2012 - 07/2011)
9.	Williams, Michael: 2 articles (01/2012 - 07/2011)
10.	Hellriegel, Edward: 1 article (10/2016)

Related Diseases

1.	Cognitive Dysfunction 07/14/2011 - "Optimization of a novel series of pyridazin-3-one histamine H(3) receptor (H(3)R) antagonists/inverse agonists identified 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (8a, CEP-26401; irdabisant) as a lead candidate for potential use in the treatment of attentional and cognitive disorders. "
2.	Schizophrenia (Dementia Praecox) 01/01/2012 - "CEP-26401 may also have therapeutic utility in treating schizophrenia or as adjunctive therapy to approved antipsychotics."
3.	Sleep Initiation and Maintenance Disorders (Insomnia) 10/01/2016 - "CEP-26401 was generally well tolerated up to 0.5 mg/day with most common treatment related adverse events being headache and insomnia. "
4.	Headache (Headaches) 10/01/2016 - "CEP-26401 was generally well tolerated up to 0.5 mg/day with most common treatment related adverse events being headache and insomnia. "

Related Drugs and Biologics

1.	6- (4- (3- (2- methylpyrrolidin- 1- yl)propoxy)phenyl)- 2H- pyridazin- 3- one
2.	Antipsychotic Agents (Antipsychotics)
3.	Histamine (Histamine Dihydrochloride)

Related Therapies and Procedures

1.	Therapeutics